Related Experiment Videos
Successful treatment of cardiac involvement in dermatomyositis with rituximab
Zahi Touma1, Thurayya Arayssi, Lina Kibbi
1American University of Beirut Medical Center, Department of Internal Medicine, Division of Rheumatology, PO Box 11-0236 Riad El-Solh, Beirut 1107 2020, Lebanon.
Abstract:
Polymyositis and dermatomyositis are autoimmune inflammatory myopathies characterized by muscle weakness and inflammation. Current recommended therapy includes corticosteroids as mainstay treatment in addition to immunosuppressant. We present herein a 25year-old female with dermatomyositis and cardiac involvement resistant to disease modifying anti-rheumatic drugs and anti-tumor necrosis factor-alpha. She was treated with anti-CD20 monoclonal antibody, rituximab. The patient demonstrated a remarkable clinical and laboratory response. B-cell depletion therapy with rituximab may be a viable option in patients with dermatomyositis and heart disease.
Related Concept Videos
Myocarditis III: Medical Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Rheumatic Heart Disease III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Myocarditis IV: Nursing Management